Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open Label Dose Escalation Study of Oral Treatment With BIBF 1120 in Combination With Standard Treatment of Paclitaxel and Carboplatin in Patients With Advanced Gynaecological Malignancies

NCT02182245 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02182245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02182245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open Label Dose Escalation Study of Oral Treatment With BIBF 1120 in Combination With Standard Treatment of Paclitaxel and Carboplatin in Patients With Advanced Gynaecological Malignancies
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2005
Completion date
Not reported
Enrollment
22 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

genital neoplasms, female